1. Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease 
Peter A. McCullough, MD, MPH, Christopher T. Chan, MD, Eric D. Weinhandl, PhD, MS, John M. Burkart, MD, George L. Bakris, MD 
American Journal of Kidney Diseases 
Volume 68, Issue 5, Pages S5-S14 (November 2016)
DOI: /j.ajkd
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Rates of death and cardiovascular hospitalization on the day after the 2-day gap in dialysis treatment and on all other days.4
American Journal of Kidney Diseases  , S5-S14DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Distribution of primary cause of death in hemodialysis patients, 2011 to
American Journal of Kidney Diseases  , S5-S14DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Effects of intensive versus conventional hemodialysis on left ventricular mass in the Frequent Hemodialysis Network (FHN) Daily Trial,37 FHN Nocturnal Trial,38 and Canadian trial of nocturnal hemodialysis.39 Estimated treatment effects (solid dots) and associated 95% confidence intervals (solid lines) are displayed at the bottom.
American Journal of Kidney Diseases  , S5-S14DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

5. Figure 4
Relative hazards of cause-specific cardiovascular hospitalization for short daily hemodialysis (SDHD) versus in-center hemodialysis (CIHD)45 and versus peritoneal dialysis (PD).47 Solid lines represent 95% confidence intervals around estimated hazard ratios (solid dots).
American Journal of Kidney Diseases  , S5-S14DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions